Clinical trials: Eosinophilic Asthma
Asthma; Eosinophilic
SIM0718 Treatment of Asthma Clinical Study
Phase III clinical study of SIM0718 asthma
- Trial name
- NCT06488755
- Testing
- SIM0718 injection
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
Understanding how Interleukin-5 blockade modulates both immune and metabolic pathways may clarify the multidimensional impact of biologic therapy in severe eosinophilic asthma.
- Trial name
- NCT05063981
- Testing
- Mepolizumab
- Where
- 2 sites in Italy
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as…
- Conditions
- Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- ROSY-F (NCT07444567)
- Testing
- Benralizumab
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma, Severe Asthma
Fasenra: An Asthma Study
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma.
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Trial name
- NCT07654842
- Testing
- Budesonide-albuterol, Benralizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Endeavor Health
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Asthma With Eosinophilic Phenotype
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
- Trial name
- NCT06653322
- Testing
- HR-1703
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma; Eosinophilic
REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM)
In this program of research, the investigators aim to answer the question: In patients with asthma aged 18-80, how do the lung airways and vessels respond to biologic therapy and what role does age and asthma duration have in…
- Trial name
- ReNORM (NCT07174713)
- Testing
- Biologic Therapy
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Severe Eosinophilic Asthma, Psychological Distress
Severe Asthma, MepolizumaB and Affect: SAMBA Study
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners.
- Conditions
- Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
- Trial name
- SAMBA (NCT04680611)
- Testing
- no study intervention. Patients receive standard clinical care
- Where
- 6 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Severe Eosinophilic ACOS (Asthma-COPD Overlap)
Blood Exosomal Multi-omics and Lung Radiomics for Predicting Efficacy and Prognosis of Severe Eosinophilic ACOS With Biologics
Firstly, to screen blood exosomal multi-omics (transcriptomics, proteomics, metabolomics) and lung radiomics (HRCT, Xe129MRI) biomarkers that can predict efficacy and prognosis in severe eosinophilic ACOS (asthma-COPD overlap)…
- Trial name
- ACOS (NCT07602881)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eosinophilic Asthma, Chronic Sinusitis
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequently described as unified airway inflammatory diseases. Both heavily impacts quality of life with substantial productivity loss.
- Conditions
- Eosinophilic Asthma, Chronic Sinusitis, Eosinophilic Rhinitis
- Trial name
- PLEIAD (NCT04187976)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Lille
Asthma, Asthma; Eosinophilic
Mepolizumab and Physical Activity in Severe Asthma
Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects.
- Trial name
- TEXAS (NCT05404763)
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Lille
Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma
Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
The goal of this observational study is to learn about clinical and functional outcomes in patients with Chronic rhinosinusitis with nasal polyps and comorbid Severe Eosinophilic Asthma and patients with Chronic rhinosinusitis…
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma, Chronic Rhinosinusitis Without Nasal Polyps
- Trial name
- MepoRiNaPAs (NCT06069310)
- Testing
- Mepolizumab 100 MG
- Where
- 2 sites in Greece
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Severe Eosinophilic Asthma
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden.
- Trial name
- EMPOWAIR (NCT05440656)
- Testing
- Cohort
- Where
- 13 sites in Greece
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
- Trial name
- NCT05002621
- Testing
- Observational
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca